Inovio Biomedical H5N1 Avian Influenza DNA Vaccine Receives Korean Approval to Begin Clinical Trials (Business Wire via Yahoo! Finance) SAN DIEGO----Inovio Biomedical Corporation , a leader in DNA vaccine design, development and delivery, announced today that its affiliate VGX International Inc. has received approval in Korea to begin a Phase I clinical trial in healthy volunteers for Inovio’s SynCon™ preventive DNA vaccine targeting H5N1 avian influenza. [News Source]